New scan could spot hidden amyloid in heart and organs

NCT ID NCT05758493

Recruiting now Diagnosis Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a radioactive imaging agent called Iodine-124 evuzumitide (AT-01) in 150 people with systemic amyloidosis. The goal is to see how well it detects amyloid deposits in the heart and other organs using PET/MRI or PET/CT scans. If accurate, it could become a new tool for diagnosing and tracking this rare disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iodine-124 evuzumitide (AT-01), a radioactive imaging agent
What this could lead to: If successful, this could provide a more accurate and non-invasive way to diagnose cardiac amyloidosis, helping doctors detect the disease earlier and monitor its spread.
What could go wrong: This is a Phase 2 diagnostic study, not a treatment trial. The imaging agent may not prove accurate enough to replace current methods, and results may not apply to all types of amyloidosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyloidosis familial amyloid neuropathy primary systemic amyloidosis wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOIDOSIS TRANSTHYRETIN AMYLOIDOSIS

Contacts and locations

Locations

Oregon Health & Science University
RECRUITING

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.